3 results
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
The goal of this investigation is to show that Hemospray is effective in achieving initial hemostasis rates equivalent to standard of care treatment and a decreased rate of further bleed when compared to standard of care up to 72 hours after…
The objective of this study is three-fold: 1) Assess measurement settings and develop the data processing chain to detect contrast signals in the left-ventricular wall with contrast-enhanced high-frame rate echocardiography. Determine whether this…